CN1188411A - 去氧孕烯的压制干颗粒片 - Google Patents

去氧孕烯的压制干颗粒片 Download PDF

Info

Publication number
CN1188411A
CN1188411A CN96194942A CN96194942A CN1188411A CN 1188411 A CN1188411 A CN 1188411A CN 96194942 A CN96194942 A CN 96194942A CN 96194942 A CN96194942 A CN 96194942A CN 1188411 A CN1188411 A CN 1188411A
Authority
CN
China
Prior art keywords
desogestrel
granule
tablet
sheet
granulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96194942A
Other languages
English (en)
Other versions
CN1119998C (zh
Inventor
P·迪哈恩
C·P·希斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of CN1188411A publication Critical patent/CN1188411A/zh
Application granted granted Critical
Publication of CN1119998C publication Critical patent/CN1119998C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及通过滚筒压紧或通过压制得到的含有去氧孕烯的干颗粒压制片剂或颗粒剂,它能够用生产方法制备,其中方法的第一步是使用高压把去氧孕烯任选与其他活性化合物和/或赋型剂压紧,然后在第二步中粉碎成颗粒,此后在第三步中用本领域已知的方法把颗粒制成片剂或填入胶囊。

Description

去氧孕烯的压制干颗粒片
本发明涉及含有去氧孕烯的压制干颗粒片及其生产方法。
去氧孕烯是一种避孕的甾类，具有Desogen、Marvelon、Mercilon和Gracial各种商标的制剂被广泛使用。
人们发现去氧孕烯具有转化成片剂和颗粒的倾向。当片芯或颗粒含有非常低剂量的去氧孕烯时，这是特别有意义的。用去氧孕烯作活性成分的片剂一般含有25-150μg，且典型的是25，50，75，100或150μg的去氧孕烯。对去氧孕烯来说，已经用作避孕或HRT(激素替代疗法)药物中的活性成分，在它的安全性和可靠性方面，这是不能接受的。例如，在半衰期间损失10％的活性物质就会对该片剂中活性组分量产生巨大影响，并且片剂中活性成份的量少于发挥全部活性的量。
现在已经发现将含有去氧孕烯的干混物压缩能够用来防止从该片剂或颗粒向环境中转化去氧孕烯。除了去氧孕烯，该片剂或颗粒还能含有雌激素。
雌激素的例子包括炔雌醇、β-雌二醇、炔雌醇甲醚(17α-乙炔基雌二醇3-甲醚)、雌酮、雌二醇、戊酸雌二醇和具有雌激素活性的其他化合物。优选的雌激素是炔雌醇和β-雌二醇。
本文所用的“转化”包括去氧孕烯过早地留下剂量单位的任何过程。
术语“剂量单位”一般指适合作人或动物单一剂量的物理不连续单位，的每一剂量含有算出产生所需效果的预定量的活性物质。这种剂量单位的例子是片剂、颗粒剂、粉剂和丸剂。
制备各种剂量单位的方法和组分对本领域普通技术人员来说是熟知的。例如，在Remingtons(第18版，A.R.Gennaro编辑的，MackPublishing Co.Easton，Pa，1990)第1633到1665页中已经描述了制备片剂和丸剂的方法和组分。
包括在压片混合物和最终剂量单位中的甾类的浓度当然取决于它的使用目的和该剂量单位的最终大小。用于剂量单位中的去氧孕烯的量对本领域普通技术人员也是熟知的。
本发明的片芯或颗粒一般含有稀释剂和任选的粘合剂。片芯或颗粒剂也将优选包括崩解剂。
稀释剂或“填料赋型剂”是加到单位剂量中来增加颗粒的和所得到的剂量单位的体积的并改善干躁-粘合特性的试剂。在这方面优选使用的稀释剂是乳糖。其他稀释剂包括甘露醇、山梨醇、(喷雾干燥的)乳糖、(微晶)纤维素、乙基纤维素、木糖醇、淀粉糖、淀粉、淀粉-衍生物、右旋糖、果糖、碳酸钙、磷酸钙，NaCaPO4，蔗糖及其混合物。该稀释剂一般占所得到的含甾类粒剂重量的70-95％。
粘合剂是用来把粘合性能赋予该颗粒和片剂并导致物理更稳定的剂量单位的试剂，它包括羟丙基纤维素、直链淀粉、淀粉、聚烯吡酮(聚乙烯吡咯烷酮)、羟丙基甲基纤维素、明胶、聚乙二醇、乙基纤维素、阿拉伯胶、明胶、甘油和淀粉为主的粘合剂。用于本发明的优选粘合剂是聚乙烯吡咯烷酮。粘合剂一般占所得到的含甾类片芯或颗粒重量的0.5-20％，并优选0.5到5％。
崩解的试剂或“崩解剂”是加到片剂中使它在给药后容易碎裂或崩解的物质或这种物质的混合物。一般这种试剂是改良的或未改良的淀粉、粘土、交联的PVP、改良或未改良的纤维素、树胶或藻酸。目前最优选的试剂是玉米淀粉、马铃薯淀粉、小麦淀粉和改良的淀粉。崩解剂一般占所得到的片剂混合物重量的5到50％，优选5到15％。
人们需要一种简单的生产方法，这种方法不需要用有机溶剂或水的湿粒制法并且不需要另外的干燥步骤。本发明涉及这种方法并提供含有去氧孕烯的压制的片剂或颗粒剂。更具体的是本发明涉及一种生产含有去氧孕烯的颗粒剂、胶囊或片剂的方法，所制备的产物中还任选有其他活性化合物和/或赋型剂，其中该方法的第一步是把去氧孕烯，任选与其他活性化合物和/或赋型剂混合，接着用高压压制，然后，在第二步将其粉碎成颗粒，之后第三步用本领域的已知方法把与润滑剂混合后的颗粒制成片剂或填入胶囊。
本方法比现有技术的方法较便宜，现有技术的方法包括分离的制粒步骤、有机溶剂或水或更昂贵的赋型剂以及干燥步骤。而且，本发明能够容易扩大。并且不使用有机溶剂，本发明方法提供了具有最小环境问题的工艺，而颗粒有改善的稳定性。
在多数情况中，不需要使用润滑剂，但为了防止在滚筒压缩期间去氧孕烯和/或雌激素粉末在滚筒上的粘着，可向该粉末中以2至0.01％w/w，并优选约0.25％w/w的量加入少量润滑剂，优选硬脂酸镁、硬脂酸、氢化蓖麻油、滑石或其混合物。
优选使用压制或滚筒压缩方法来压紧该粉末和任选的润滑剂(如硬脂酸镁或硬脂酸)。该方法的第一步是干法制粒步骤，其中没有使用溶剂并把含有去氧孕烯的粉末制成颗粒。在本发明方法中，压紧后得到去氧孕烯、雌激素和赋型剂的片或圆片，任选将这些片或圆片碎成不规则的细粒(颗粒)。作为一种附加的步骤，可把该颗粒筛分成所需的细粒或细粉，然后将细粉再循环到滚压料斗或压片机中。
在压紧过程中，所用的压力是一个重要的参数。用压力使滚筒间的温度增加。滚筒压力的增加造成压缩片的较高强度，从而造成低易碎性。而且，随着压力，产率增长。得到低易碎性和低降解以及高产率的适当压力是在约0.5和500MPa(兆帕斯卡)。优选的压力是约200-400MPa，这会得到最小的活性损失和最大产率。
压制机能够是任何压制机，例如凸型或凹型，具有直线或曲线形滚筒或粉末运送螺旋桨的不同外观的压制机。Alexander WP120滚筒压制机似乎是一种方便的压制机。
一般不得不把压制的粉末粉碎成较小的颗粒。这种破碎步骤对颗粒大小的分布很重要，颗粒的大小分布取决于所用的破碎方法。原则上，任何破碎机都能使用，例如锥形或滚筒型破碎机最好与Alexander Roller压制机的破碎筛、Comil锥形制粒机或Frewitt破碎筛一起使用。使用这类筛时，一般很容易得到大约50％的产率。筛出不能使用的细粉并将其再循环到压制步骤中。
优选的实施例是压制药片，用重功率的压片设备压制块或大片，然后研磨成所需颗粒特征。
颗粒可以压片或填入胶囊，例如填入硬胶囊如明胶胶囊。
 按照上述方法，制备具有下列组分的去氧孕烯片：
    片Amg     片Bmg     片Cmg
  去氧孕烯炔雌醇淀粉葡糖酸钠硬脂酸甘露糖醇qasd硬脂酸镁PharmatoseDCL-11qsad     0.1500.0301.301.3065.0--     0.1500.0301.301.3065.0--     0.1500.0301.20--0.3060.0
本发明的片A是这样制得的：在Turbula混合机中用10％的甘露糖醇预混合去氧孕烯和EE并用250μm的筛筛分该混合物。把筛过的块与剩余的甘露糖醇和淀粉葡糖酸钠混合，接着在Lodiger混合机中再与1.5％的硬脂酸(＜250μm)混合。以340MPa压制压缩物。破碎该块后，收集小于710μm的干颗粒并在Turbula混合机中与0.5％的硬脂酸混合。在KorschPH-106的压片机上把该混合物压成重为65mg的片。
本发明的片B(现有技术的片)是这样得到的：在Turbula混合机中用大约10％的甘露糖醇预混合去氧孕烯和EE并用250μm的筛筛分该混合物。把筛过的块与剩余的甘露糖醇和淀粉葡糖酸钠混合，接着在Lodiger混合机中再与1.5％的硬脂酸(＜250μm)混合。在Turbula混合机中与0.5％的硬脂酸进行混合。在Korsch PH-106的压片机上把该混合物压成重为65mg的片。
本发明的片C(现有技术的片)是这样得到的：在Gral高剪切混合机中用喷雾干燥的乳糖(Pharmatose DCL-11)预混合去氧孕烯和EE。之后，在混合物中也混合其他赋型剂并随后直接压成重为65mg的片。
把片A(本发明)的升华特性与现有技术的片B和片C的相比。在70℃15kPa压力下把样品存放72小时。在4℃的冷指状物上收集升华气体并定量分析升华的去氧孕烯的量：
    升华的去氧孕烯的量(％在起始片中的量)
     A            B            C9.0          12.3         15.2
本发明的片剂(A)显示了比现有技术中的片B和C改善的升华特性并由此预料有改善的半衰期。

Claims (4)

1.通过滚筒压紧或通过压制得到的含有去氧孕烯的干颗粒压制片剂或颗粒剂。
2.一种生产含有去氧孕烯的干颗粒压制片剂或颗粒剂的方法，其特征在于：方法的第一步是使用高压把去氧孕烯和任选与其他活性化合物和/或赋型剂压紧，然后在第二步中粉碎成颗粒，此后在第三步中用本领域已知的方法把颗粒制成片剂或填入胶囊。
3.根据权利要求2的方法，其中用滚筒压紧或压制压缩去氧孕烯和任选与其他活性化合物和/或赋型剂。
4.根据权利要求2的方法，其中所用的压力在约0.5至约500MPa之间，优选约200-400Mpa。
CN96194942A 1995-06-22 1996-06-18 去氧孕烯的压制干颗粒片 Expired - Fee Related CN1119998C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95201698 1995-06-22
EP95201698.8 1995-06-22

Publications (2)

Publication Number Publication Date
CN1188411A true CN1188411A (zh) 1998-07-22
CN1119998C CN1119998C (zh) 2003-09-03

Family

ID=8220405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96194942A Expired - Fee Related CN1119998C (zh) 1995-06-22 1996-06-18 去氧孕烯的压制干颗粒片

Country Status (22)

Country Link
US (1) US6063403A (zh)
EP (1) EP0833642B1 (zh)
JP (1) JP4116672B2 (zh)
KR (1) KR100421526B1 (zh)
CN (1) CN1119998C (zh)
AT (1) ATE215825T1 (zh)
AU (1) AU710710B2 (zh)
BR (1) BR9609208A (zh)
CA (1) CA2224269C (zh)
CZ (1) CZ289133B6 (zh)
DE (1) DE69620607T2 (zh)
DK (1) DK0833642T3 (zh)
ES (1) ES2175106T3 (zh)
HK (1) HK1008923A1 (zh)
HU (1) HU223943B1 (zh)
NO (1) NO316052B1 (zh)
NZ (1) NZ312113A (zh)
PL (1) PL184558B1 (zh)
PT (1) PT833642E (zh)
RU (1) RU2159618C2 (zh)
TR (1) TR199701659T1 (zh)
WO (1) WO1997000682A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9022098A (en) * 1997-08-20 1999-03-08 Fuisz Technologies Ltd. Process for improving flow and compression of tableting compositions
WO2000059920A2 (en) * 1999-04-06 2000-10-12 Akzo Nobel N.V. Orally active 7.alpha.-alkyl androgens
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
US6358526B1 (en) 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
US7999003B2 (en) * 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
KR101202607B1 (ko) 2005-03-03 2012-11-20 마나테크 인코포레이티드 영양 보조제의 조절된 방출을 위한 방법 및 조성물
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
JP2009535408A (ja) * 2006-05-04 2009-10-01 ノバルティス アクチエンゲゼルシャフト 薬剤を製造するための加熱ローラー圧縮方法
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DE4222298B4 (de) * 1992-07-08 2005-11-03 Robert Bosch Gmbh Verfahren zur Dämpfung von auftretenden Ruckelschwingungen für Brennkraftmaschinen
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.

Also Published As

Publication number Publication date
ES2175106T3 (es) 2002-11-16
NZ312113A (en) 1998-06-26
PL184558B1 (pl) 2002-11-29
HUP9901350A2 (hu) 1999-08-30
DE69620607T2 (de) 2002-09-19
DK0833642T3 (da) 2002-06-10
NO975986D0 (no) 1997-12-19
NO316052B1 (no) 2003-12-08
EP0833642B1 (en) 2002-04-10
NO975986L (no) 1997-12-19
HU223943B1 (hu) 2005-03-29
TR199701659T1 (xx) 1998-03-21
KR100421526B1 (ko) 2004-05-20
DE69620607D1 (de) 2002-05-16
WO1997000682A1 (en) 1997-01-09
US6063403A (en) 2000-05-16
CN1119998C (zh) 2003-09-03
AU710710B2 (en) 1999-09-30
PT833642E (pt) 2002-08-30
CA2224269A1 (en) 1997-01-09
JPH11507933A (ja) 1999-07-13
CA2224269C (en) 2008-06-17
RU2159618C2 (ru) 2000-11-27
JP4116672B2 (ja) 2008-07-09
KR19990028214A (ko) 1999-04-15
PL324345A1 (en) 1998-05-25
HUP9901350A3 (en) 2000-03-28
CZ416597A3 (cs) 1998-06-17
MX9710411A (es) 1998-07-31
CZ289133B6 (cs) 2001-11-14
HK1008923A1 (en) 1999-05-21
AU6356696A (en) 1997-01-22
BR9609208A (pt) 1999-05-11
ATE215825T1 (de) 2002-04-15
EP0833642A1 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
CN1119998C (zh) 去氧孕烯的压制干颗粒片
Dhopeshwarkar et al. Evaluation of xanthan gum in the preparation of sustained release matrix tablets
CN1101681C (zh) 用湿制粒法制备剂量单位的方法
CA1287582C (en) Sustained release compositions comprising hydroxypropyl cellulose ethers
US6623754B2 (en) Dosage form of N-acetyl cysteine
US6358526B1 (en) Method of making tablets and tablet compositions produced therefrom
CA1285483C (en) Sustained release compositions
US5085869A (en) Pharmaceutical granulate
US7179486B1 (en) Process for preparing sustained release tablets
JP2000506540A (ja) バルサルタンの固体経口剤形
CN1319005A (zh) 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物
Landin et al. Influence of microcrystalline cellulose source and batch variation on the tabletting behaviour and stability of prednisone formulations
EP0196546B1 (en) Pharmaceutical tableting method
EP0265951B1 (en) Granular tricalcium phosphate compositions suitable for direct compression tableting
EP1541161B1 (en) Tablet composition containing chinese orthodox medicine extract and process for producing the same
EP3459530B1 (en) Burst drug release compositions
DE202021003994U1 (de) Dosierungsform mit verlängerter Freisetzung von Tapentadol-Phosphorsäuresalz
MXPA97010411A (en) Grinding tablets of granulation in compressed dry
JPH05221853A (ja) 崩壊性良好な生薬類含有造粒物
Kawashima et al. Preparation of a sustained-release matrix tablet of acetaminophen with pulverized low-substituted hydroxypropylcellulose via dry granulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ORGANON NV

Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP.

Effective date: 20061229

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061229

Address after: Holland

Patentee after: Organon NV

Address before: Holland Arnhem

Patentee before: Akzo Nobel N. V.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030903